Current Report Filing (8-k)
December 15 2017 - 2:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December
13, 2017
Commission
File #:
000-53723
TAURIGA
SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Florida
(State
or other jurisdiction of incorporation)
30-0791746
(IRS
Employer Identification Number)
555
Madison Avenue, 5
th
Floor
New
York, NY
(Address
of principal executive office)
Tel:
(917) 796-9926
(Registrant’s
telephone number)
39
Old Ridgebury Road
Danbury,
CT 06180
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Item
2.01 Completion of Acquisition or Disposition of Assets
Tauriga
Sciences, Inc. (the “Company”) participated in a $15,000,000 underwritten public offering by Vistagen Therapeutics
Inc. (NASDAQ: VTGN) (“Vistagen”), which closed on December 13, 2017. The Company invested $480,000 USD of its net
cash position and purchased 320,000 registered shares of Vistagen common stock, as well as warrants exercisable immediately for
a period of five (5) years from the date of issuance for up to 320,000 additional shares of common stock of Vistagen. The Warrants
carry an exercise price of $1.50 per share, and do not incorporate a cashless exercise feature. The Company is in possession of
the registered securities as of the closing date.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
December 15, 2017
|
TAURIGA
SCIENCES, INC.
|
|
|
|
|
By:
|
/s/
Seth M. Shaw
|
|
|
Seth
M. Shaw
|
|
|
Chief
Executive Officer
|
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024